PUBLISHED BY
Zhao H, Kakodkar P, Wang E, Zhang D, Niemann M, Webster D, Pearce T, Shoker A, Keown P, Sherwood K, Wu F, Lewis C and Mostafa A
PUBLISHED IN
Frontiers in Immunology
PATIENTS
594
ABSTRACT
HIGHLIGHTS
17.5% of recipients developed dnDSA, most frequently targeting HLA-DQ (49.3%).
Higher Epregistry and PIRCHE-T2 scores were significantly associated with dnDSA development.
ROC-derived cutoffs across all three algorithms enabled stratification into low-, intermediate-, and high-risk groups (AUC 0.601–0.648; p < 0.05).
Patients exceeding cutoffs across all models demonstrated significantly lower dnDSA-free and ABMR-free survival (log-rank p < 0.001).
PIRCHE-T2 scores were independently associated with T-cell mediated rejection.
